Radiotherapy and immune checkpoint blockades: a snapshot in 2016
Radiation Oncology Journal
;
: 250-259, 2016.
Article
in English
| WPRIM
| ID: wpr-33377
ABSTRACT
Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Radiotherapy
/
United States Food and Drug Administration
/
T-Lymphocytes, Cytotoxic
/
Carcinoma, Non-Small-Cell Lung
/
Programmed Cell Death 1 Receptor
/
Melanoma
/
Antibodies, Monoclonal
Limits:
Humans
Language:
English
Journal:
Radiation Oncology Journal
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS